[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-cerebrovascular-accident\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-cerebrovascular-accident":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,77,107,134],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100648984","comparative-evaluation-of-the-efficacy-and-safety-of-high-power-short-duration-radiofrequency-ablation-and-standard-low-power-ablation-in-catheter-treatment-of-atrial-fibrillation-100648984",false,"NCT07728539","Comparative Evaluation of the Efficacy and Safety of High-Power Short-Duration Radiofrequency Ablation and Standard Low-Power Ablation in Catheter Treatment of Atrial Fibrillation","Inclusion Criteria:\n\n* Age over 18 years old;\n* Atrial fibrillation resistant to antiarrhythmic therapy;\n* Paroxysmal form of atrial fibrillation;\n* Persistent form of atrial fibrillation;\n* The patient's consent to participate in the study.\n\nExclusion Criteria:\n\nExclusion Criteria:\n\n* Age under 18 and over 80 years old;\n* The presence of another cardiac pathology requiring surgical treatment;\n* Congenital heart defects;\n* Previous \"open\" cardiac surgery;\n* Bone marrow diseases;\n* Pathology of the blood coagulation system;\n* The left ventricular ejection fraction is less than 40%;\n* Moderate to severe renal insufficiency (creatinine clearance \\\u003C50 ml\u002Fmin);\n* Drug-resistant hypertension (despite hypotensive therapy);\n* Organically altered mitral valve;\n* There are reasons to assume that the patient will not show up for subsequent visits (control points of the study) for various reasons;\n* The patient's participation in another clinical trial.","ALL","18 Years","70 Years",{"count":19,"type":20},196,"ESTIMATED","INTERVENTIONAL",[23],"NA","Atrial fibrillation (AF) is the most common cardiac arrhythmia and represents one of the leading causes of cardiovascular morbidity and mortality. According to current data, AF is associated with approximately 20% of all ischemic strokes, while the risk of stroke in patients with this arrhythmia is increased fivefold. Ischemic stroke in patients with AF is characterized by a more severe clinical course, more frequently results in death, is associated with significant disability, and carries a higher risk of recurrence compared with strokes of other etiologies. Consequently, the risk of death in patients with AF-associated stroke is doubled, while the economic costs of treatment increase by an average of 1.5 times.\n\nThe aim of the present study is to perform a comparative evaluation of the efficacy of two interventional treatment strategies for atrial fibrillation: very high-power short-duration radiofrequency ablation (90 W) and conventional low-power radiofrequency ablation (35-45 W) for pulmonary vein isolation using the \"CLOSE protocol\" approach with a non-fluoroscopic navigation system. The efficacy of the interventions will be assessed both in the early postoperative period and during long-term follow-up over 12 months.",[26,27,28,29,30],"Atrial Fibrillation (AF)","Stroke","Acute Cerebrovascular Accident","Atrial Fibrillation Recurrent","Death",[32,33,34,35],"Radiofrequency ablation","high-power short-duration ablation","very high-power short-duration ablation","atrial fibrillation","RECRUITING","2026-07-22",{"date":39,"type":40},"2026-07-27","ACTUAL",{"date":42,"type":40},"2026-06-15",{"date":44,"type":20},"2029-06-01",{"name":46,"class":47},"Bakulev Scientific Center of Cardiovascular Surgery","OTHER_GOV",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":48},"100535528","radiofrequency-and-cryoablation-of-the-posterior-wall-of-the-left-atrium-100535528","NCT06253000","Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium","Comparative Analysis of Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium in Patients With Persistent Atrial Fibrillation","Inclusion Criteria:\n\n* Age over 18 years old;\n* Atrial fibrillation resistant to antiarrhythmic therapy;\n* Persistent and long-persisting form of atrial fibrillation;\n* The patient's consent to participate in the study.\n\nExclusion Criteria:\n\n* Age under 18 and over 80 years old;\n* The presence of another cardiac pathology requiring surgical treatment;\n* Congenital heart defects;\n* Previous \"open\" cardiac surgery;\n* Bone marrow diseases;\n* Pathology of the blood coagulation system;\n* The left ventricular ejection fraction is less than 40%;\n* Moderate to severe renal insufficiency (creatinine clearance \\\u003C50 ml\u002Fmin);\n* Drug-resistant hypertension (despite hypotensive therapy);\n* Organically altered mitral valve;\n* There are reasons to assume that the patient will not show up for subsequent visits (control points of the study) for various reasons;\n* The patient's participation in another clinical trial.","80 Years",{"count":58,"type":20},158,[23],"Atrial fibrillation (AF) is the cause of 20% of strokes, and the risk of stroke in a person suffering from this arrhythmia increases by 5 times. Ischemic stroke in patients with AF is often fatal and, compared with stroke of other etiology, leads to the most pronounced disability and more often recurs. Accordingly, the risk of death in patients with AF-related stroke is 2 times higher, and treatment costs increase 1.5 times.\n\nThe main interventional method of treating AF, available in most medical institutions, is the use of radio frequency and\u002For cryoenergy to eliminate destructive damage to the left atrium (LA).\n\nThe aim of this study is to compare two different interventional methods and identify predictors of recurrence in patients with persistent and long-term AF.",[27,28,62,30,29],"Transient Ischemic Attack",[35,64,65,66,67,68],"radiofrequency ablation","cryoablation","left atrium","the posterior wall of the left atrium","atrial remodeling","2026-07-17",{"date":71,"type":40},"2026-07-20",{"date":73,"type":40},"2023-06-10",{"date":75,"type":20},"2026-12-30",{"name":46,"class":47},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":48},"100634025","investigation-of-brain-blood-flow-changes-in-acute-ischemic-stroke-patients-after-successful-endovascular-thrombectomy-100634025","NCT07534319","Investigation of Brain Blood Flow Changes in Acute Ischemic Stroke Patients After Successful Endovascular Thrombectomy","RESTORE-AIS","Inclusion Criteria:\n\n* Male and female subjects \\>18 years old.\n* Acute ischemic stroke related to a new occlusion of the internal carotid artery, middle cerebral artery (M1- and\u002For M2-segment), or both.\n* Eligibility and performance of endovascular thrombectomy.\n* Achievement of successful recanalization, defined as mTICI score ≥2b\n* Written informed consent of the patient or when the patient is not able to participate in the consenting procedure, the written authorization of a family member. Foreign speaking patients should be included by a person with sufficient German language proficiency to act as a translator.\n\nExclusion Criteria:\n\n* Documented evidence or a confirmed willingness of the patient not to participate in any scientific study.\n* Standard contraindications for MRI, such as pacemaker, metallic prothesis, glaucoma, metallic tattoo dyes, verbal confirmed pregnancy. Unwilling or unable to cooperate with breathing manoeuvres.\n* Major cardiopulmonary diseases, such as severe uncontrolled asthma bronchiale, severe chronic obstructive lung disease (i.e., GOLD stage ≥III), diffuse interstitial lung disease, pulmonary embolism, acute\u002Fsubacute myocardial infarction, or severe heart failure (i.e., NYHA class ≥III).\n* Symptomatic increased intracranial pressure.\n* Presence of intracranial haemorrhage type ≥2 according to the Heidelberg classification.\n* New onset of seizure.",{"count":85,"type":20},100,"OBSERVATIONAL","Introduction:\n\nEndovascular thrombectomy (EVT) is an effective treatment strategy to mitigate the ischemic tissue damage caused by the acute cerebral large-vessel occlusion. However, in clinical practice, nearly half of the patients do not experience adequate neurological improvement despite successful recanalization - a phenomenon termed reperfusion failure or clinically ineffective reperfusion. Given the clinical relevance of this phenomenon and the absence of a standardized imaging diagnostic method to identify it, our project aims to explore the potential role of blood oxygenation-level dependent cerebrovascular reactivity (BOLD-CVR) as novel imaging biomarker for studying reperfusion failure.\n\nStudy population:\n\nAdult patients with acute ischemic stroke of the ICA, MCA or with tandem occlusion who have undergone a successful recanalization, described as mTICI score ≥2b.\n\nObjective(s):\n\nPrimary objective: to longitudinally observe blood flow changes derived from BOLD-CVR imaging following successful endovascular thrombectomy in patients with large-vessel occlusion acute ischemic stroke (LVO-AIS) during the early post-treatment phase and assess their association with clinical outcome 90 days post-EVT.\n\nSecondary objective: to compare BOLD-CVR findings with those obtained from the clinical standard dynamic susceptibility contrast (DSC) MR perfusion imaging acquired in the same examination session as well as other imaging techniques included in the standard post-treatment imaging protocol at our institution.\n\nOutcomes:\n\nClinical outcomes:\n\n* 90-day functional outcome.\n* Functional outcome at hospital discharge.\n* Neurological deterioration during hospitalization.\n* Radiologically confirmed haemorrhagic transformation within the reperfused tissue.\n* Radiologically confirmed infarct lesion progression within the reperfused tissue.\n* Additionally, DSC MR perfusion imaging parameters and other standard hemodynamic imaging parameters will be considered as imaging outcomes\n\nStudy design:\n\nSingle-center prospective observational cohort study\n\nMeasurements and procedures:\n\nIncluded patients will undergo a total of 3 BOLD-CVR examinations: 72 hours, 7 days, and 90 days after EVT. Participation in the final examination will mark the end of the subject's involvement in the study. Clinical outcomes will be prospectively collected as per established institutional patient management protocols: during hospitalization, at discharge, and at the cerebrovascular outpatient clinic at 3 months.\n\nNumber of Participants:\n\nTarget sample size: 100 patients\n\nGiven the observational study design and exploratory nature of this project, no sample size calculation can be performed. The provided target sample size (N = 100) has been estimated considering the inclusion of as many consecutive subjects as possible.\n\nStudy period: 2.5 years The investigators aim to enroll a target sample size of 100 patients over a period of 2.5 years. This translates to an inclusion of 3-4 patients per month, with the last three months allocated for the follow-up of the last included patients.\n\nStudy Centre:\n\nClinical Neuroscience Center, Department of Neurosurgery, University Hospital Zurich\n\nStatistical Considerations:\n\nThe association between BOLD-CVR findings and clinical outcomes will be investigated using regression analyses.",[28,89,90,91],"Thrombectomy","Cerebral Revascularization","No Reflow Phenomenon",[93,89,94,90,91,95,96],"Acute Ischemic Stroke","Reperfusion Failure","BOLD-CVR","Advanced Haemodynamic Imaging","2026-04-09",{"date":99,"type":40},"2026-04-16",{"date":101,"type":40},"2025-06-01",{"date":103,"type":20},"2027-12-01",{"name":105,"class":106},"University of Zurich","OTHER",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":133},"100603239","phrenic-nerve-stimulation-for-reducing-ventilation-duration-in-acute-cerebral-infarction-a-multicenter-randomized-controlled-trial-100603239","NCT07133932","Phrenic Nerve Stimulation for Reducing Ventilation Duration in Acute Cerebral Infarction: A Multicenter Randomized Controlled Trial","Transcutaneous Electrical Phrenic Nerve Stimulation for Reducing Mechanical Ventilation Duration in Acute Cerebral Infarction: A Multicenter Randomized Controlled Trial","EDP-VENT","Inclusion Criteria:\n\n* age ≥ 18 years old\n* no gender restrictions\n* patient diagnosed with acute cerebral infarction (within 30 days of onset) through cranial CT or MRI\n* duration of mechanical ventilation ≥ 24 hours\n* patient or their legal guardian agrees to participate in the study and signs an informed consent form\n\nExclusion Criteria:\n\n* there are other significant conditions that affect diaphragm function, such as severe malnutrition, irreversible respiratory pump failure caused by medullary or cervical cord injury, and irreversible damage to the phrenic nerve\n* significant agitation cannot be combined with transcutaneous electrical phrenic nerve stimulation\n* severe skin damage or infection at the electrode placement site\n* previous presence of severe lung disease (such as severe COPD, interstitial lung disease, pulmonary embolism, etc.), severe heart failure (NYHA Class IV)\n* sepsis or shock requiring high-dose vasopressors\n* the terminal state of the disease or expected survival period does not exceed 7 days\n* pacemaker implantation\n* pregnant or lactating women\n* patients whose family members express their willingness to withdraw for treatment",{"count":116,"type":20},590,[23],"The goal of this clinical trial is to learn if non-invasive phrenic nerve stimulation works in adult acute cerebral infarction participants undergoing mechanical ventilation. It will also learn about the safety of non-invasive phrenic nerve stimulation. The main questions it aims to answer are：\n\n1. Can non-invasive phrenic nerve stimulation shorten the duration of ventilator use and improve long-term prognosis?\n2. What medical problems do participants have when taking non-invasive phrenic nerve stimulation? Researchers will compare non-invasive phrenic nerve stimulation to a sham stimulation to see if non-invasive phrenic nerve stimulation works.\n\nParticipants will:\n\n1. Receive 14 days of non-invasive phrenic nerve stimulation or sham stimulation\n2. Visit the clinic or call for follow-up at 90 days of onset",[120,121,28,122],"Cerebral Infarction","Mechanical Ventilation","Adult","NOT_YET_RECRUITING","2025-08-13",{"date":126,"type":40},"2025-08-21",{"date":128,"type":20},"2025-09-01",{"date":130,"type":20},"2027-12-31",{"name":132,"class":106},"Xuanwu Hospital, Beijing",9,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":21,"phases":145,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":48},"100574386","to-assess-the-effectiveness-and-safety-of-catheter-based-focal-intracranial-hypothermia-combined-with-endovascular-reperfusion-therapy-for-patients-with-acute-anterior-circulation-large-artery-occlusion-100574386","NCT06758609","To Assess the Effectiveness and Safety of Catheter-based Focal Intracranial Hypothermia Combined with Endovascular Reperfusion Therapy for Patients with Acute Anterior Circulation Large Artery Occlusion","Local Hypothermia and Endovascular Recanalization for Acute Large Artery Occlusive Stroke-A Multicenter, Prospective, Open-label, Blinded-Endpoint, Randomized Controlled Trial","CHILL-ART","Inclusion Criteria:\n\n1. Age ≥18 and ≤85 years old.\n2. Symptoms of sudden focal or general neurological impairment.\n3. There may be a causal relationship between vascular occlusion and nerve function defect.\n4. Time from symptom onset to randomization ≤24h.\n5. The National Institutes of Health Stroke Scale (NIHSS) score was ≥6 points before randomization.\n6. According to the judgment of the clinician, the operation path is reasonable, and the operation and operation related instruments can reach the disease smoothly.\n7. Patients or their guardians can understand the purpose of the trial, voluntarily participate and sign a written informed consent, and are capable of receiving clinical follow-up.\n8. Prior to randomization, CTA, MRA, or DSA confirmed the presence of anterior circulatory large vessel occlusion (internal carotid artery or M1segment).\n9. The symptoms are aggravated by recurrent cerebral infarction in the same drainage basin and\u002For the pathogenesis is caused by decreased blood perfusion.\n\nExclusion Criteria:\n\n1. Pre stroke mRS\\>1 score.\n2. There are acute infarcts in both cerebral hemispheres and\u002For anterior and posterior circulation.\n3. NIHSS≤6 points.\n4. Cerebral hemorrhage\u002Fsubarachnoid hemorrhage was confirmed by CT or MRI. 5.The presence of active bleeding, severe anemia, coagulation dysfunction, or an uncorrected bleeding tendency (Presence of at least one of the following laboratory tests: hemoglobin \\\u003C 10g \u002Fdl, platelet count \\\u003C 100,000 \u002Fμl, uncorrected INR\\>1.5, PT\\> 1 minute above the upper limit of normal, or heparin-related thrombocytopenia).\n\n6.Patients with heart function of grade 1 or above, or with a clear history of acute or chronic heart dysfunction, are at greater risk of acute heart failure or fluid perfusion intolerance as determined by clinicians.\n\n7\\. Severe heart, liver, kidney disease. 8.With malignant diseases such as malignant tumors, the expected survival time is less than 3 months.\n\n9.Participating in other clinical trials, in the investigational phase or in the follow-up phase.","85 Years",{"count":144,"type":20},262,[23],"A multicenter, prospective, open-label, blinded-endpoint, randomized controlled trial to assess the effectiveness and safety of catheter-based focal intracranial hypothermia combined with endovascular reperfusion therapy for patients with acute anterior circulation large artery occlusion.",[28,93,148,149],"Internal Carotid Artery","Middle Cerebral Artery Occlusion","2024-12-27",{"date":152,"type":40},"2025-01-06",{"date":154,"type":40},"2024-12-01",{"date":156,"type":20},"2026-06-30",{"name":158,"class":106},"Guangdong Second Provincial General Hospital"]